NDA 207793 · Ipsen
Onivyde
Irinotecan Hydrochloride · Intravenous
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Oct 22, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
2,083
325 Phase 3, 315 recruiting
FAERS reports
9,837
9,369 serious, 1,809 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE NEUTROPENIA AND SEVERE DIARRHEA Neutropenia Severe and life-threatening neutropenia, including fatal neutropenic sepsis and fatal neutropenic fever, has occurred in patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin and in combination with fluorouracil and leucovorin. Withhold ONIVYDE for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. Diarrhea Severe and life-threatening diarrhea has occurred in patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin and in combination with fluorouracil and leucovorin. Do not administer ONIVYDE to patients with bowel obstruction. Withhold ONIVYDE for diarrhea of Grade 2-4 severity. Administer loperamide for late diarrhea of...
What it is approved for
From the label in effect Mar 3, 2025.
ONIVYDE is indicated, in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma. ONIVYDE is indicated, in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. Limitations of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. [see Clinical Studies (14) ] . ONIVYDE is a topoisomerase inhibitor indicated: in combination with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma, ( 1 ) in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. ( 1 ) Limitation of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. ( 1 )
Mechanism: Irinotecan liposome injection is a topoisomerase 1 inhibitor encapsulated in a lipid bilayer vesicle or liposome. Topoisomerase 1 relieves torsional strain in DNA by inducing single-strand breaks. Irinotecan and its active metabolite SN-38 bind reversibly to the topoisomerase 1-DNA complex and prevent re-ligation of the single-strand breaks, leading to exposure time-dependent double-strand DNA damage and cell death. In mice bearing human tumor xenografts, irinotecan liposome administered at irinotecan HCl-equivalent doses 5-fold lower than irinotecan HCl achieved similar intratumoral exposure...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 13, 2024 Supplement 16 · Efficacy OrphanLabelLetter
- Oct 22, 2015 Original approval · Type 5 - New Formulation or New Manufacturer · priority review OrphanReviewLabelLetter
1 products under this application
- ONIVYDE · IRINOTECAN HYDROCHLORIDE EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) · INJECTABLE, LIPOSOMAL, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Irinotecan" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00079274 · 3,397 participants · Start Feb 2004 · Primary completion Nov 2012
Drug: irinotecan hydrochloride; oxaliplatin and 4 more · For: Adenocarcinoma of the Colon; Stage III Colon Cancer
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 894 sites in all
- Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal CancerPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00975897 · 3,240 participants (planned) · Start Jul 2009 · Primary completion Aug 2010
Drug: bevacizumab; cetuximab and 4 more · For: Colorectal Cancer
Sites: Leeds, United Kingdom; Belfast, United Kingdom; Cardiff, United Kingdom
- Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood TestPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT07340567 · 2,450 participants (planned) · Start Jul 20, 2026 · Primary completion Nov 1, 2032
Drug: Capecitabine; Oxaliplatin and 2 more · For: Colorectal Cancer
Sites: Villejuif, France; Gothenburg, Sweden; Lund, Sweden · 5 sites in all
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00265850 · 2,334 participants · Start Nov 2005 · Primary completion Feb 2015
Drug: bevacizumab; cetuximab and 2 more · For: Colorectal Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Fort Smith, Arkansas · 683 sites in all
- Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerPivotal-lookingStatus unknown
Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
NCT00091312 · 1,976 participants (planned) · Start Jun 2004
Drug: FOLFIRI regimen; fluorouracil and 2 more · For: Colorectal Cancer
Sites: Cairo, Egypt; Boulogne-Billancourt, France; Dijon, France · 9 sites in all
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePivotal-lookingRecruiting
NRG OncologyAcademic, hospital or other
NCT05174169 · 1,912 participants (planned) · Start Jul 8, 2022 · Primary completion Mar 10, 2029
Drug: mFOLFOX6 3-6 month; CAPOX 3 month and 3 more · For: Stage III Colon Cancer
Sites: Birmingham, Alabama; Daphne, Alabama; Fairhope, Alabama · 1,085 sites in all
- Combination Chemotherapy in Treating Patients With Advanced Colorectal CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00003594 · 1,691 participants · Start Oct 1998 · Primary completion Oct 2004
Drug: irinotecan; fluorouracil and 2 more · For: Colorectal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 466 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea1,225
- off label use980
- myelosuppression719
- nausea645
- vomiting569
- malignant neoplasm progression548
- febrile neutropenia538
- death512
- neutropenia468
- neuropathy peripheral443
- disease progression426
- fatigue420
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 9 |
| 2006 | 6 |
| 2007 | 2 |
| 2008 | 143 |
| 2009 | 84 |
| 2010 | 123 |
| 2011 | 224 |
| 2012 | 291 |
| 2013 | 243 |
| 2014 | 158 |
| 2015 | 335 |
| 2016 | 312 |
| 2017 | 313 |
| 2018 | 414 |
| 2019 | 488 |
| 2020 | 548 |
| 2021 | 638 |
| 2022 | 863 |
| 2023 | 1,022 |
| 2024 | 1,083 |
| 2025 | 1,475 |
| 2026 | 1,052 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Onivyde (Irinotecan Liposomal)
2024 spending
$2.2M
Beneficiaries
47
167 claims
Per beneficiary
$47,526
$275.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $293,344 |
| 2021 | $442,132 |
| 2022 | $757,636 |
| 2023 | $1,358,977 |
| 2024 | $2,233,736 |
Part B: Onivyde (Irinotecan Liposomal) · HCPCS J9205
2024 spending
$87.9M
Beneficiaries
2,165
11,509 claims
Per beneficiary
$40,586
2024 ASP limit $63.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $53,152,629 |
| 2021 | $56,731,827 |
| 2022 | $63,047,522 |
| 2023 | $74,036,599 |
| 2024 | $87,869,105 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A, Hubner RA, Siveke JT, et al. · Eur J Cancer 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, et al. · Lancet 2016 · Clinical Trial, Phase III, Multicenter Study
- Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Mastrantoni L, Chiaravalli M, Spring A, et al. · Lancet Oncol 2024 · Systematic Review, Comparative Study
- Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
Ohba A, Ozaka M, Mizusawa J, et al. · J Clin Oncol 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F, Cremolini C, Masi G, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Ipsen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.